Faculty, Pediatrics, Medicine
|Complete Name:||Regino Primitivo Gonzalez-Peralta, M.D.|
|Phones:||UF Business Telephone: (352) 273-9350 |
|Postal:||UF Business Mailing|
Po Box 100296
Gainesville, FL 326100296
Dr. Gonzalez-Peralta's academic pursuits are focused on developing a research and clinical program in Pediatric Hepatology. His initial laboratory work defined the importance of immune-mediated mechanisms in the pathogenesis of liver-cell damage in chronic hepatitis C. His laboratory also developed a novel technique to study HCV heterogeneity (quasispecies) based on single-strand conformational polymorphism. Using this technique, his group was one of the first to demonstrate that HCV heterogeneity played an important role in the pathobiology of this viral infection, particularly as it pertained to treatment response. Despite progress of the understanding of the molecular biology of HCV infection, it became apparent that the study of HCV replication and pathogenesis was hampered by a lack of a suitable animal or in vitro model of viral infection. Thus, his laboratory then focused on developing an efficient cell culture model of HCV replication, with financial support from the NIH, University of Florida and the Blowitz-Ridgeway Foundation. Although Dr. Gonzalez-Peralta derived very encouraging preliminary results in the research laboratory, he began to ‘miss’ the interactions with his patients and their families. Accordingly, as a way to reconcile personal and academic-research interests, Dr. Gonzalez-Peralta became actively involved in studying the clinical impact of HCV infection in children. With support from the pharmaceutical industry and NIH, he has participated in several investigator-initiated and industry-sponsored trials of interferon and pegylated interferon alone or with ribavirin. Through the participation in the NIH-sponsored PEDS-C consortium, his group spearheaded pivotal studies assessing the effects of HCV infection and antiviral therapy on the quality of life of children infected with this virus. More recently he has also focused on studying hepatitis B virus (HBV) infection in children. He is actively involved in trials assessing pharmacokinetic, safety, and efficacy of nucleos(t)ide in children with chronic HBV infection. In addition, his team has been an active member in the Studies for Liver Transplantation (SPLIT), a consortium of North American centers that prospectively tracks the outcome of children who need (and undergo) liver replacement.
There is additional contact information available for Regino Gonzalez-Peralta, but you are not authorized to see it. Use the LOGIN button inthe upper right of this page and you will be returned here after login.